PMID- 27197163
OWN - NLM
STAT- MEDLINE
DCOM- 20170728
LR  - 20220409
IS  - 1538-7445 (Electronic)
IS  - 0008-5472 (Linking)
VI  - 76
IP  - 11
DP  - 2016 Jun 1
TI  - Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer 
      Patients Undergoing Adjuvant Chemotherapy.
PG  - 3122-6
LID - 10.1158/0008-5472.CAN-16-0294 [doi]
AB  - Pattern recognition receptors allow the innate immune system to perceive the 
      presence of microbial products and to launch the first steps of the defense 
      response. Some pattern recognition receptors also sense endogenous ligands that 
      are released from uninfected dying cells, thereby activating immune responses 
      against dead-cell antigens. This applies to toll-like receptors 3 and 4 (TLR3, 
      TLR4), which sense double-stranded RNA and high-mobility group protein B1 
      (HMGB1), respectively, as well as to formyl peptide receptor-1 (FPR1), which 
      interacts with Annexin A1 (ANXA1) from dead cells. Breast cancer patients who 
      bear loss-of-function alleles in TLR3, TLR4, and FPR1 exhibit a reduced 
      metastasis-free and overall survival after treatment with anthracycline-based 
      adjuvant chemotherapy. These genetic defects are epistatic with respect to each 
      other, suggesting that they act on the same pathway, linking chemotherapy to a 
      therapeutically relevant anticancer immune response. Loss-of-function alleles in 
      TLR4 and FPR1 also affect the prognosis of colorectal cancer patients treated 
      with oxaliplatin-based chemotherapy. Altogether, these results support the idea 
      that conventional anticancer treatments rely on stimulation of anticancer immune 
      responses to become fully efficient. Cancer Res; 76(11); 3122-6. (c)2016 AACR.
CI  - (c)2016 American Association for Cancer Research.
FAU - Vacchelli, Erika
AU  - Vacchelli E
AD  - Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. 
      Equipe 11 labellisee par la Ligue Nationale contre le Cancer, Centre de Recherche 
      des Cordeliers, Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, 
      Paris, France. Universite Pierre et Marie Curie, Paris, France.
FAU - Enot, David P
AU  - Enot DP
AD  - Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. 
      Equipe 11 labellisee par la Ligue Nationale contre le Cancer, Centre de Recherche 
      des Cordeliers, Paris, France. Metabolomics and Cell Biology Platforms, Gustave 
      Roussy Cancer Campus, Villejuif, France.
FAU - Pietrocola, Federico
AU  - Pietrocola F
AD  - Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. 
      Equipe 11 labellisee par la Ligue Nationale contre le Cancer, Centre de Recherche 
      des Cordeliers, Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, 
      Paris, France. Universite Pierre et Marie Curie, Paris, France.
FAU - Zitvogel, Laurence
AU  - Zitvogel L
AD  - Gustave Roussy Cancer Campus, Villejuif, France. Faculte de Medecine, Universite 
      Paris-Saclay, Kremlin-Bicetre, France. INSERM, U1015, Villejuif, France. Center 
      of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, 
      France.
FAU - Kroemer, Guido
AU  - Kroemer G
AD  - Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. 
      Equipe 11 labellisee par la Ligue Nationale contre le Cancer, Centre de Recherche 
      des Cordeliers, Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, 
      Paris, France. Universite Pierre et Marie Curie, Paris, France. Metabolomics and 
      Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. Pole de 
      Biologie, Hopital Europeen Georges Pompidou, AP-HP, Paris, France. Karolinska 
      Institute, Department of Women's and Children's Health, Karolinska University 
      Hospital, Stockholm, Sweden. kroemer@orange.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160516
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Receptors, Pattern Recognition)
SB  - IM
MH  - Breast Neoplasms/drug therapy/metabolism/*pathology
MH  - Chemotherapy, Adjuvant
MH  - Female
MH  - Humans
MH  - Prognosis
MH  - Receptors, Pattern Recognition/*metabolism
EDAT- 2016/05/20 06:00
MHDA- 2017/07/29 06:00
CRDT- 2016/05/20 06:00
PHST- 2016/02/02 00:00 [received]
PHST- 2016/02/24 00:00 [accepted]
PHST- 2016/05/20 06:00 [entrez]
PHST- 2016/05/20 06:00 [pubmed]
PHST- 2017/07/29 06:00 [medline]
AID - 0008-5472.CAN-16-0294 [pii]
AID - 10.1158/0008-5472.CAN-16-0294 [doi]
PST - ppublish
SO  - Cancer Res. 2016 Jun 1;76(11):3122-6. doi: 10.1158/0008-5472.CAN-16-0294. Epub 
      2016 May 16.